UroToday - Response to Docetaxel/Carboplatin-Based Chemotherapy as First- and Second-Line Therapy in Patients with Metastatic Hormone-Refractory Prostate Cancer - Abstract

[Guest guest]

http://www.urotoday.com/browse_categories/prostate_cancer/response_to_docetaxelcarboplatinbased_chemotherapy_as_first_and_secondline_therapy_in_patients_with_metastatic_hormonerefractory_prostate_cancer__abstract.html

Wednesday, 30 January 2008

Lank

Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber

Cancer Institute and Harvard Medical School, Boston, MA 02115, USA

To

evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as

first- and second-line chemotherapy for patients with hormone-refractory

prostate cancer (HRPC).

We

retrospectively identified all patients with HRPC treated with DC-based

chemotherapy at the Dana-Farber Cancer Institute. Regimens either included

estramustine (EDC) or not (DC). We identified patients who received EDC as

first-line chemotherapy and patients who received DC as second-line or

subsequent chemotherapy. Patients

treated with EDC received 20-70 mg/m(2) docetaxel every 1-4 weeks, estramustine

140 mg three times daily and carboplatin (area under the curve, AUC), (4-6)

every 3-4 weeks. Patients treated

with DC received docetaxel 50-70 mg/m(2) and carboplatin AUC (4-6) every 3-4

weeks.

In all,

the study included 54 patients; 24 received EDC and 30 DC (median age 62.8 and

66.9 years, respectively); their prostate-specific antigen (PSA) level at the

start of chemotherapy was 112.7 and 213.3 ng/mL, respectively. There were

declines of >or=50% in PSA level in 88% and 20% in the two groups,

respectively. The median overall survival was 17.7 and 14.9 months in the EDC

and DC groups, respectively. The most common reversible grade 4 toxicity with

either regimen was neutropenia (4% and 7% in EDC and DC, respectively).

DC-based

chemotherapy is well tolerated and active in HRPC. Adding carboplatin to

docetaxel provides an additional activity in 20% of patients as a second-line

or subsequent chemotherapy.

Written

by

Nakabayashi M, Sartor O, us S, Regan MM, McKearn D, Ross RW, Kantoff PW,

Taplin ME, Oh WK.

Reference

BJU

Int. 2008 Feb;101(3):308-12

doi:10.1111/j.1464-410X.2007.07331.x

PubMed

Abstract

PMID:18184327